{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:57:25Z","timestamp":1778770645150,"version":"3.51.4"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Malignant mesothelioma (MM) is a tumor originating from the pleura, peritoneum, or pericardial cavity. It is divided into diffuse and localized malignant mesothelioma, with four subtypes in diffuse MM: epithelioid, sarcomatoid, desmoplastic, and biphasic, with biphasic being less common. The onset of this tumor is insidious, and the prognosis is extremely poor in some cases, with a median survival of 6\u201318\u00a0months and no standard treatment options in the past.<\/jats:p><jats:p><jats:bold>Aims:<\/jats:bold> We report a case of peritoneal malignant mesothelioma that was successfully treated with transformative therapy. We also review the literature in the hope of providing reference for the treatment and pathological diagnosis of such patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The case of the peritoneal malignant mesothelioma was processed and reported in the routine manner for biopsy specimens at different stages.<\/jats:p><jats:p><jats:bold>Results and conclusion:<\/jats:bold> We report a case of a malignant tumor originating in the hepatorenal recess, which was diagnosed as biphasic malignant mesothelioma through a biopsy. Immunohistochemical testing showed PD-L1 expression. After multidisciplinary discussion, the patient received transformative treatment, including a trial of combined immunotherapy. The tumor significantly shrank, and the patient obtained a chance for curative surgical resection. Microscopic examination showed significant collagenization in the lesion area, with almost no residual tumor. After 19\u00a0months of comprehensive treatment, the patient developed multiple fluffy opacities under the pleura of both lungs. Transthoracic core needle biopsy under CT guidance, the pathology showed organizing pneumonia, considering it as delayed interstitial pneumonitis due to immunotherapy based on previous treatment history. Successful comprehensive treatment was achieved for this case of peritoneal malignant mesothelioma, and the patient has been alive without evidence of disease for 33\u00a0months, with long-term follow-up. In this process, the pathologist had three opportunities for pathological diagnosis, which required understanding the patient\u2019s medical history, being attentive to the clinical purpose of the specimen, and providing accurate responses to morphological changes at different stages, along with corresponding descriptions and diagnoses to provide effective information for clinical treatment.<\/jats:p>","DOI":"10.3389\/pore.2023.1611577","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T04:11:28Z","timestamp":1704687088000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical and pathological observation of conversion therapy for malignant peritoneal mesothelioma: a case report and literature review"],"prefix":"10.3389","volume":"29","author":[{"given":"Minying","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongkui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingyong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00428-020-02980-9","article-title":"Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas","volume":"478","author":"Fernandez-Cuesta","year":"2021","journal-title":"Virchows Arch"},{"key":"B2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/path.1700120212","article-title":"A malignant tumour arising from the endothelium of the peritoneum, and producing a mucoid ascitic fluid","volume":"12","author":"Miller","year":"1908","journal-title":"J Pathol Bacteriol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/CEJ.0b013e3282f0c0a2","article-title":"US mesothelioma patterns 1973-2002: indicators of change and insights into background rates","volume":"17","author":"Teta","year":"2008","journal-title":"Eur J Cancer Prev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ctrv.2011.10.006","article-title":"Diffuse malignant peritoneal mesothelioma--an update on treatment","volume":"38","author":"Mirarabshahii","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"B5","first-page":"1","article-title":"Clinicopathological study on 100 Japanese patients with peritoneal mesothelioma in Japan","volume":"30","author":"Naka","year":"1984","journal-title":"Gan No Rinsho"},{"key":"B6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1183\/09031936.99.13352399","article-title":"Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort","volume":"13","author":"Metintas","year":"1999","journal-title":"Eur Respir J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00000421-199508000-00009","article-title":"Malignant peritoneal mesothelioma after Thorotrast exposure","volume":"18","author":"Stey","year":"1995","journal-title":"Am J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.1996.14.7.2098","article-title":"Malignant mesothelioma following treatment for Hodgkin's disease","volume":"14","author":"Weissmann","year":"1996","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/(sici)1097-4644(20000201)76:2<181::aid-jcb2>3.3.co;2-0","article-title":"Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations","volume":"76","author":"Shivapurkar","year":"1999","journal-title":"J Cell Biochem"},{"key":"B10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/ijc.20820","article-title":"Predictions of mortality from pleural mesothelioma in Italy: a model based on asbestos consumption figures supports results from age-period-cohort models","volume":"115","author":"Marinaccio","year":"2005","journal-title":"Int J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jama.1946.02870300021006","article-title":"Special article","volume":"131","author":"Price","year":"1946","journal-title":"J Am Med Assoc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/oem.17.4.260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the north western cape province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/030089160308900307","article-title":"Clinical presentation of peritoneal mesothelioma","volume":"89","author":"Acherman","year":"2003","journal-title":"Tumori"},{"key":"B14","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/annonc\/mdp307","article-title":"Malignant peritoneal mesothelioma: a multicenter study on 81 cases","volume":"21","author":"Manzini","year":"2010","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.3760\/cma.j.cn112137-20210210-00405","article-title":"Chinese expert consensus on the diagnosis and treatment of diffuse malignant peritoneal mesothelioma","volume":"101","year":"2021","journal-title":"Chin Med J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jtho.2021.09.012","article-title":"Molecular characterization of peritoneal mesotheliomas","volume":"17","author":"Offin","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/modpathol.2016.188","article-title":"Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X","volume":"30","author":"Joseph","year":"2017","journal-title":"Mod Pathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/gcc.22068","article-title":"RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12)","volume":"52","author":"Panagopoulos","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/jso.21167","article-title":"Malignant abdominal mesothelioma: defining the role of surgery","volume":"99","author":"Rodr\u00edguez","year":"2009","journal-title":"J Surg Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3322\/caac.21400","article-title":"The burden of rare cancers in the United States","volume":"67","author":"DeSantis","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1200\/JCO.2003.04.150","article-title":"Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy","volume":"21","author":"Feldman","year":"2003","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00384-014-2029-1","article-title":"Advances in malignant peritoneal mesothelioma","volume":"30","author":"Cao","year":"2015","journal-title":"Int J Colorectal Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.6004\/jnccn.2012.0008","article-title":"Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma","volume":"10","author":"Turner","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"B24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program","volume":"7","author":"J\u00e4nne","year":"2005","journal-title":"Clin Lung Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1158\/2159-8290.CD-21-0331","article-title":"Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma","volume":"11","author":"Raghav","year":"2021","journal-title":"Cancer Discov"},{"key":"B26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41416-020-01130-x","article-title":"Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy","volume":"124","author":"White","year":"2021","journal-title":"Br J Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e026779","DOI":"10.1136\/bmjopen-2018-026779","article-title":"Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial","volume":"9","author":"de Boer","year":"2019","journal-title":"BMJ Open"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.ejso.2017.05.009","article-title":"Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: a RENAPE study","volume":"43","author":"Valmary-Degano","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3760\/cma.j.issn.2096-3076.2019.04.008","article-title":"A case of cardiac toxicity caused by immune checkpoint inhibitors in the treatment of malignant mesothelioma","volume":"3","author":"Si","year":"2019","journal-title":"Chin J Heart Fail Cardiomyopathy"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2023.1611577\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T14:34:24Z","timestamp":1704983664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2023.1611577\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":31,"alternative-id":["10.3389\/pore.2023.1611577"],"URL":"https:\/\/doi.org\/10.3389\/pore.2023.1611577","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"article-number":"1611577"}}